4-Chloro-6-methoxy-2-Methylpyrimidin-5-amine | CAS:88474-31-1

We serve 4-Chloro-6-methoxy-2-Methylpyrimidin-5-amine CAS:88474-31-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Chloro-6-methoxy-2-Methylpyrimidin-5-amine

Synonyms:
5-amino-4-chloro-6-methoxy-2-methylpyrimidine
4-chloro-6-methoxy-2-methyl-pyrimidin-5-ylamine
4-Chlor-6-methoxy-2-methyl-pyrimidin-5-ylamin
4-Chloro-6-methoxy-2-methyl-5-pyrimidinamine
5-Pyrimidinamine,4-chloro-6-methoxy-2-methyl
2-methyl-4-methoxy-5-amino-6-chloropyrimidine
 
Molecular Formula: C6H8ClN3O
Molecular Weight: 173.60000
 
Density: 1.331g/cm3
Boiling point: 271.6ºC at 760 mmHg
Flash point: 118.1ºC

Items of Analysis Standard of Analysis Test Results
Appearance White to off-white solid Conforms
Assay ≥98.0% 98.57%
Conclusion Conforms to Factory Standard
 



Contact us for information like 4-Chloro-6-methoxy-2-Methylpyrimidin-5-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-methyl-4-methoxy-5-amino-6-chloropyrimidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Chloro-6-methoxy-2-methyl-5-pyrimidinamine Use and application,5-amino-4-chloro-6-methoxy-2-methylpyrimidine technical grade,usp/ep/jp grade.


Related News: According to the “2013-2018 New Drug Review Summary” report, from 2013 to 2018, new drug applications have shown a year-on-year growth trend. In 2018, domestically produced Class 1 new drugs have declared 225 varieties, the highest in 10 years.5-((E)-4-((1r,4r)-4-(allyloxy)cyclohexyl)styryl)-1,3-difluoro-2-isothiocyanatobenzene manufacturer The Philippines reported its first Wuhan coronavirus fatality on Sunday.5-chloro-1-(4-fluorophenyl)-N-methylpyrazole-4-carboxamide supplier The Philippines reported its first Wuhan coronavirus fatality on Sunday.5-[(4-isopropylphenyl)sufonyl]-imidazo[1′,2′:1,6]pyrido[2,3-b]pyrazin-6-amine vendor “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.In recent years, with the increasing number of patent medicines whose patents have expired, the variety and quantity of generic drugs have also increased rapidly, which has brought huge market opportunities to the API market and the output of APIs has continued to increase.